EGFR and non-small cell lung carcinoma: Detection of resistance mutations such as T790M and C797S in the plasma of patients with NSCLC who progress on EGFR TKIs also has promising utility in identifying which patients are suitable for subsequent therapies, both following initial diagnosis and following disease progression with first-line TKI therapy [11–14].